{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:00:06Z","timestamp":1772164806967,"version":"3.50.1"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HHS | NIH | National Cancer Institute","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["5K12CA086913"],"award-info":[{"award-number":["5K12CA086913"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor and VEGFR inhibitor combinations are effective treatments for patients with metastatic renal cell carcinoma (mRCC). This phase I\/II clinical trial evaluated the safety and efficacy of pembrolizumab and cabozantinib in patients with mRCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>Eligible patients had mRCC with clear-cell or non-clear cell histology, adequate organ function, Eastern Cooperative Oncology Group 0\u20131 performance status, and no prior exposure to pembrolizumab or cabozantinib. The primary endpoint was objective response rate (ORR) at the recommended phase II dose (RP2D). Secondary endpoints included safety, disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Forty-five patients were enrolled. A total of 40 patients were treated at the RP2D of pembrolizumab 200 mg i.v. every 3 weeks and cabozantinib 60 mg orally once daily, 38 of which were evaluable for response. The ORR was 65.8% [95% confidence interval (CI), 49.9\u201378.8] for all evaluable patients [78.6% as first-line therapy, 58.3% as second-line therapy]. The DCR was 97.4% (95% CI, 86.5\u201399.9). Median DoR was 8.3 months (interquartile range, 4.6\u201315.1). At a median follow-up of 23.54 months, the median PFS was 10.45 months (95% CI, 6.25\u201314.63) and median OS was 30.81 months (95% CI, 24.2\u2013not reached). The most common grade 1 and\/or 2 treatment-related adverse events (TRAE) were diarrhea, anorexia, dysgeusia, weight loss, and nausea. The most common grade 3 and\/or 4 TRAEs were hypertension, hypophosphatemia, alanine transaminase elevation, diarrhea, and fatigue. There was one grade 5 TRAE of reversible posterior encephalopathy syndrome related to cabozantinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Pembrolizumab and cabozantinib treatment in patients with mRCC demonstrated encouraging preliminary efficacy and a manageable toxicity profile comparable with other available checkpoint inhibitor-tyrosine kinase inhibitor combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov Identifier: NCT03149822 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03149822<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study evaluated the safety and effectiveness of the combination of pembrolizumab and cabozantinib in patients with mRCC. The safety profile was manageable. The combination showed promising activity with an objective response rate of 65.8%, median PFS of 10.45 months, and median OS of 30.81 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0060","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T09:07:10Z","timestamp":1684919230000},"page":"1004-1012","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Phase I\/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-867X","authenticated-orcid":true,"given":"Elizabeth R.","family":"Kessler","sequence":"first","affiliation":[{"name":"1University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9028-8098","authenticated-orcid":true,"given":"Eryn","family":"Callihan","sequence":"additional","affiliation":[{"name":"1University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5937-7916","authenticated-orcid":true,"given":"Junxiao","family":"Hu","sequence":"additional","affiliation":[{"name":"2University of Colorado Cancer Center Biostatistics Core, University of Colorado Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8430-1040","authenticated-orcid":true,"given":"Corbin","family":"Eule","sequence":"additional","affiliation":[{"name":"1University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4293-4568","authenticated-orcid":true,"given":"Geetika","family":"Srivastava","sequence":"additional","affiliation":[{"name":"3UCHealth Cancer Care and Hematology Clinic, Memorial Hospital Central, Colorado Springs, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0352-0585","authenticated-orcid":true,"given":"Douglas J.","family":"Kemme","sequence":"additional","affiliation":[{"name":"4UCHealth Cancer Center Harmony Campus, Poudre Valley Hospital, Fort Collins, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8474-3669","authenticated-orcid":true,"given":"Praveena","family":"Iruku","sequence":"additional","affiliation":[{"name":"3UCHealth Cancer Care and Hematology Clinic, Memorial Hospital Central, Colorado Springs, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3113-5052","authenticated-orcid":true,"given":"Vishal","family":"Rana","sequence":"additional","affiliation":[{"name":"3UCHealth Cancer Care and Hematology Clinic, Memorial Hospital Central, Colorado Springs, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6860-5039","authenticated-orcid":true,"given":"James","family":"Moore","sequence":"additional","affiliation":[{"name":"4UCHealth Cancer Center Harmony Campus, Poudre Valley Hospital, Fort Collins, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7766-6295","authenticated-orcid":true,"given":"Steven R.","family":"Schuster","sequence":"additional","affiliation":[{"name":"4UCHealth Cancer Center Harmony Campus, Poudre Valley Hospital, Fort Collins, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9588-0730","authenticated-orcid":true,"given":"Mali","family":"Amirault","sequence":"additional","affiliation":[{"name":"1University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-9040","authenticated-orcid":true,"given":"Thomas W.","family":"Flaig","sequence":"additional","affiliation":[{"name":"1University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-3402","authenticated-orcid":true,"given":"Elaine T.","family":"Lam","sequence":"additional","affiliation":[{"name":"1University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado."},{"name":"5UCHealth Lone Tree Medical Center, Lone Tree, Colorado."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2023060814023716300_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2023060814023716300_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2023060814023716300_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"2023060814023716300_bib4","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023060814023716300_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"2023060814023716300_bib6","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023060814023716300_bib7","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"2023060814023716300_bib8","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"2023060814023716300_bib9","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"2023060814023716300_bib10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"2023060814023716300_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2023060814023716300_bib12","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"2023060814023716300_bib13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023060814023716300_bib14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11864-013-0268-y","article-title":"Potential of new therapies like anti-PD1 in kidney cancer","volume":"15","author":"Gunturi","year":"2014","journal-title":"Curr Treat Options Oncol"},{"key":"2023060814023716300_bib15","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","article-title":"Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients","volume":"15","author":"Ko","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2023060814023716300_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10555-011-9281-4","article-title":"Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy","volume":"30","author":"Tartour","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"2023060814023716300_bib17","doi-asserted-by":"crossref","first-page":"492920","DOI":"10.1155\/2012\/492920","article-title":"Modulation of immunity by antiangiogenic molecules in cancer","volume":"2012","author":"Terme","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2023060814023716300_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"2023060814023716300_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"2023060814023716300_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/sim.1600","article-title":"Admissible two-stage designs for phase II cancer clinical trials","volume":"23","author":"Jung","year":"2004","journal-title":"Stat Med"},{"key":"2023060814023716300_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2023060814023716300_bib22","unstructured":"NCI. Common terminology criteria for adverse events (CTCAE), version 4.0. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm; 2021."},{"key":"2023060814023716300_bib23","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.5858\/arpa.2015-0544-OA","article-title":"Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue","volume":"140","author":"Dolled-Filhart","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"2023060814023716300_bib24","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.21.00939","article-title":"Cabozantinib in combination with atezolizumab for advanced renal cell carcinoma: results from the COSMIC-021 study","volume":"39","author":"Pal","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023060814023716300_bib25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023060814023716300_bib26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1470-2045(18)30907-0","article-title":"Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study","volume":"20","author":"Mart\u00ednez Chanz\u00e1","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023060814023716300_bib27","doi-asserted-by":"crossref","first-page":"102333","DOI":"10.1016\/j.ctrv.2021.102333","article-title":"Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: a review","volume":"103","author":"McGregor","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2023060814023716300_bib28","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023060814023716300_bib29","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.20.02363","article-title":"Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"key":"2023060814023716300_bib30","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2023060814023716300_bib31","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.juro.2006.06.028","article-title":"Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma","volume":"176","author":"Jung","year":"2006","journal-title":"J Urol"},{"key":"2023060814023716300_bib32","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.1210\/jc.2003-030910","article-title":"Clinical review 165: Markers of bone remodeling in metastatic bone disease","volume":"88","author":"Fohr","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2023060814023716300_bib33","doi-asserted-by":"crossref","first-page":"S660","DOI":"10.1016\/j.annonc.2022.07.1551","article-title":"1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC)","volume":"33","author":"Albiges","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0060\/3334185\/crc--0-0060.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/6\/1004\/3339519\/crc-23-0060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/6\/1004\/3339519\/crc-23-0060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T10:03:10Z","timestamp":1686218590000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/6\/1004\/727208\/A-Phase-I-II-Clinical-Trial-of-Pembrolizumab-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,8]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0060","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.23393638","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393641.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393629.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393626","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393632","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393635.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393638.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393632.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393626.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393623.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393629","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393623","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393635","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393647","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6686815.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393647.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393644.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6686815","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.23393644.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393638","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393626","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393635.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393638.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393632","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393641.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393647.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393647","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393635","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393623","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393632.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393629.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393629","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393623.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23393626.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}